Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Restless legs syndrome: causes and consequences

Massey, T. H. ORCID: https://orcid.org/0000-0002-9804-2131 and Robertson, N. P. ORCID: https://orcid.org/0000-0002-5409-4909 2020. Restless legs syndrome: causes and consequences. Journal of Neurology 267 (2) , pp. 575-577. 10.1007/s00415-019-09682-6

[thumbnail of s00415-019-09682-6.pdf]
Preview
PDF - Published Version
Download (331kB) | Preview

Abstract

Restless legs syndrome (RLS) of a severity requiring medical attention has a prevalence of 2–3% in Caucasian populations. This significant cause of neurological morbidity is defined by an insistent urge to move the legs, and is often accompanied by uncomfortable and unpleasant sensations deep in the legs themselves. Symptoms typically begin or worsen at rest, especially in the evening and night, and are often relieved by activities such as rubbing, stretching, or walking. There is a family history of RLS in approximately 50% of cases, suggesting genetic risk factors, and significant associations have been shown with low serum ferritin, uraemia, and pregnancy. In addition, individuals with various chronic medical conditions such as cardiovascular disease, hypertension, multiple sclerosis, Parkinson’s disease, spinal cord disease, and neuropathy have been shown to have an increased risk of RLS although proving cause-and-effect is difficult. People with RLS have impaired sleep, often associated with periodic limb movements, and increased risk of depression and anxiety, all of which combine to reduce quality of life. Treatment of RLS involves lifestyle changes, such as increased exercise, and management of chronic comorbidities. Reversible causes such as low serum ferritin should be corrected. Effective medications include dopamine agonists (pramipexole or ropinirole), α2δ agonists (gabapentin or pregabalin), or opioids. RLS symptoms can paradoxically worsen with extended use of dopamine agonists (‘augmentation’) leading to a difficult clinical situation where dopamine agonist withdrawal is required, often with opioid cover.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Publisher: Springer Verlag (Germany)
ISSN: 0340-5354
Date of First Compliant Deposit: 30 January 2020
Date of Acceptance: 31 December 2019
Last Modified: 05 May 2023 03:34
URI: https://orca.cardiff.ac.uk/id/eprint/129173

Citation Data

Cited 3 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics